Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at ...

Investors are still coming out of one of the worst bond markets in history. Between the bond market’s dismal 2022 and the stock market’s downturn from the onset of the Russia-Ukraine war, the 2020s ...